Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$5.2 million.

  • Benitec Biopharma's Change in Account Payables fell 43959.82% to -$5.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$2.4 million, marking a year-over-year decrease of 35270.99%. This contributed to the annual value of -$2.4 million for FY2025, which is 35270.99% down from last year.
  • Per Benitec Biopharma's latest filing, its Change in Account Payables stood at -$5.2 million for Q2 2025, which was down 43959.82% from $3.8 million recorded in Q1 2025.
  • Benitec Biopharma's 5-year Change in Account Payables high stood at $3.8 million for Q1 2025, and its period low was -$5.2 million during Q2 2025.
  • Its 5-year average for Change in Account Payables is $82888.9, with a median of $533000.0 in 2022.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 37694.81% in 2021, then tumbled by 46650.79% in 2024.
  • Over the past 5 years, Benitec Biopharma's Change in Account Payables (Quarter) stood at $853000.0 in 2021, then tumbled by 164.48% to -$550000.0 in 2022, then soared by 307.45% to $1.1 million in 2023, then tumbled by 157.67% to -$658000.0 in 2024, then tumbled by 696.35% to -$5.2 million in 2025.
  • Its Change in Account Payables was -$5.2 million in Q2 2025, compared to $3.8 million in Q1 2025 and -$658000.0 in Q4 2024.